Turnover: 181 million EUR (2020)
Country: Switzerland
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication, and a renowned diabetes specialist with over 30 years' experience.
Ypsomed Delivery Systems (YDS) provides a comprehensive range of technologies and services for reliable, user-friendly injection systems for self-medication. Its customers are pharmaceutical and biotech companies that develop, manufacture and market injectable therapies.
With its mylife Diabetescare brand (CHF 315 million in 2017), Ypsomed offers a comprehensive portfolio of products and services for people with diabetes.
Financial Data
DUNS: 449734631
Legal Name: YPSOMED
Address: 44 RUE LA FAYETTE , 75009 PARIS 9
Number of employees: 1800 ()
Capital: 1 000 000 EUR
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2019 | 34 026 509 EUR | 358 537 EUR | 31/03/2019 | 12 |
| 2018 | 60 903 333 EUR | 2 276 480 EUR | 31/03/2018 | 12 |
| 2017 | 32 125 695 EUR | 1 282 892 EUR | 31/03/2017 | 12 |
| 2016 | 11 659 159 EUR | 215 929 EUR | 31/03/2016 | 12 |
Studies mentioning this company
The Insulin Pump Market - France
Other companies mentioned:
- Medtronic
- Cellnovo
- Roche Diabetes Care (Roche Groupe)
- Insulet
- Ypsomed Group
- ISIS diabète (Isis Médical)
- Physidia
- Nova Medical Center
- Medtrum
- Apex Wellell
- Open APS
- Eli Lilly
- TreeFrog Therapeutics
- Boydsense